DOCSLIB.ORG

Combination Therapy of Testosterone Enanthate and Tadalafil on PDE5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combination Therapy of Testosterone Enanthate and Tadalafil on PDE5 International Journal of Impotence Research (2013) 25, 29–33 & 2013 Macmillan Publishers Limited All rights reserved 0955-9930/13 www.nature.com/ijir ORIGINAL ARTICLE Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency JW Kim1,MMOh1, MG Park2, JY Park3, JH Bae3, JJ Kim4 and DG Moon1 Several studies have suggested combination therapy with testosterone supplementation in patients not responding to PDE5 inhibitors. Considering the pathophysiological basis for testosterone supplementation, the present study aims to identify whether combination therapy allows persistence of treatment effect after testosterone discontinuation. Furthermore, we evaluated whether the degree of testosterone depletion affects treatment outcome from combination therapy. Hypogonadal patients (o350 ng dl À 1) with erectile dysfunction who previously did not respond to PDE5 inhibitors were treated with testosterone enanthate injections and daily tadalafil. Patients were stratified into two groups depending on the level of testosterone deficiency, with 250 ng dl À 1 as a reference point. Following testosterone supplementation (12 weeks) and combination therapy (12 weeks), patients with severe testosterone deficiency showed higher IIEF (International Index of Erectile Function) erectile function (EF) domain score (16.47±4.019 vs 12.36±4.051, P ¼ 0.001) and more patients responding satisfactorily to treatment by general assessment (57.9 vs 16.0%, P ¼ 0.009), despite reaching similar levels of serum total testosterone (602±169 ng dl À 1 vs 698±165 ng dl À 1, P ¼ 0.057). Testosterone supplementation was then discontinued and patients were maintained only on daily tadalafil (12 weeks). The severe depletion group maintained higher EF domain scores than baseline (13.06±3.38 vs 7.20±2.24, P ¼ 0.0004), despite testosterone levels returning to baseline. The results suggest that combination therapy was more beneficial to patients with severe testosterone depletion, possibly by improving underlying pathophysiology. International Journal of Impotence Research (2013) 25, 29–33; doi:10.1038/ijir.2012.32; published online 13 September 2012 Keywords: combination therapy; erectile dysfunction; tadalafil; testosterone enanthate INTRODUCTION MATERIALS AND METHODS Despite the success of PDE5 inhibitors in treating erectile Inclusion/exclusion criteria dysfunction, lower treatment rates have been observed for The study was conducted in accordance with the protocol approved by the diabetic (64%) and post prostatectomy patients (43%).1 Institutional Review Board of Korea University School of Medicine. To be Hypogonadism has been associated as a common etiological eligible for inclusion in the study, the men were older than 40 years and factor, and testosterone replacement in these patients have had a diagnosis of ED, suggestive by an International Index of Erectile demonstrated increased responsiveness to PDE5 inhibitors.2–4 Function (IIEF) erectile function (EF) domain score below 22, and at least 3 5 months treatment with any PDE5 inhibitor, which includes prescriptions of These studies have shown a general improvement of 34–100%. a PDE5 inhibitor equivalent to 100 mg sildenafil. Patients were also The question remains whether combination therapy allows primarily included for hypogonadism, as diagnosed by baseline testoster- fundamental recovery of erectile function. Furthermore, there is one levels of below 350 ng dl À 1. Men with Peyronie’s disease, penile a general lack of consensus in researchers as to what construes curvature or with a history of penile surgery other than circumcision were the state of hypogonadism. Interestingly, some studies have excluded, as were patients who received any form of testosterone presented that patients with more severe depletion of supplement in the past. Patients were required to discontinue any PDE5 testosterone showed better response to therapy, and conversely, inhibitors for 2 weeks before entering the study period. patients who reached higher testosterone levels during treatment 2 Study design lost treatment benefit. À 1 Our study proposed to investigate whether discontinuation Patients were divided into two groups, intermediate (o350 ng dl , X À 1 À 1 of testosterone supplementation allows persistent recovery of 250 ng dl ) and severe (o250 ng dl ) deficiency of testosterone based on baseline assessment. Both groups were given the same course of PDE5 inhibitor response, and as such, whether patients treatment and efficacy and persistence of efficacy following testosterone with severe or intermediate depletion of testosterone benefit discontinuation was observed. more from synergistic effects of testosterone repletion and PDE5 The total duration of the study was 36 weeks, divided into three phases inhibitors. of 12 weeks. Phase 1, termed the initiation period, consisted of outpatient 1Department of Urology, Korea University College of Medicine, Guro Hospital, Seoul, Korea; 2Department of Urology, Inje University College of Medicine, Seoul Paik Hospital, Seoul, Korea; 3Department of Urology, Korea University College of Medicine, Ansan Hospital, Ansan, Korea and 4Department of Urology, Korea University College of Medicine, Asam Hospital, Seoul, Korea. Correspondence: Professor DG Moon, Department of Urology, Korea University College of Medicine, Guro Hospital, Gurodong-gil 97, Guro-2-dong, Guro-gu, Seoul 152-703, Korea. E-mail: [email protected] Received 19 September 2011; revised 23 April 2012; accepted 7 August 2012; published online 13 September 2012 Tadalafil and testosterone combination therapy JW Kim et al 30 Figure 1. Patient flow chart and study design. visits every 4 weeks for intramuscular testosterone enanthate injection RESULTS only. This was followed by phase 2, termed the combination treatment Overall patient characteristics period, in which patients continued to receive intramuscular testosterone enanthate injections every 4 weeks, as well as daily tadalafil 5 mg. Phase 3, A total of 46 men (age range 41–75 years) comprised the study cohort. Twenty patients showed serum testosterone levels below termed the discontinuation period, consisted of patients receiving daily À 1 tadalafil 5 mg only, and discontinuing their testosterone supplementation 250 ng dl (severe group) and 26 patients showed testosterone À 1 (Figure 1). levels above 250 ng dl (intermediate group). Patients with one or more comorbidities comprised 91.3% (n ¼ 42). The most prevalent condition was diabetes, (n ¼ 18, 39.1%), followed by Assessments prostatic hyperplasia (n ¼ 16, 34.8%) and hypertension (n ¼ 10, Before treatment initiation, and at the termination of each 12-week phase, 21.7%). Although all 4 patients with no significant medical history baseline and treatment efficacy was assessed by the IIEF 15-item showed intermediate levels of testosterone deficiency, there was questionnaire, validated and translated into Korean. The primary efficacy no significant predominance of comorbidities between the two measure was assessed by the EF domain score. Secondary measures included the Sexual Encounter Profile Question 2 (SEP2: Were you able groups (Table 1). to insert your penis into your partner’s vagina?) and Question 3 (SEP3: Only 2 patients dropped out during combination therapy, and Did your erection last long enough for you to complete intercourse 10 more patients dropped out after testosterone was discon- with ejaculation?), and patient responses to the Global Assessment tinued, with only 73.9% (34 out of 46) completing the entire study Question (GAQ: Has the treatment you have been taking over the past duration. While a total of seven patients were lost during follow- study interval improved your erections?). Blood tests for total testosterone up for unknown reasons, five patients requested removal from and free testosterone was performed at initiation and at the end of phases study complaining of lack of treatment benefits. Overall patient 2 and 3. characteristics and characteristics by cohort divided by degree of testosterone deficiency is presented in Table 1 (Figure 1). Statistical methods Factors associated with treatment success were assessed at completion Effect of combination therapy (V3) of combination therapy and at completion of study. The initial variables examined at enrollment were compared between treatment success The initial EF domain scores showed no significant difference and failure groups. Statistical analyses were performed with P-values between the two groups (P ¼ 0.16). Effect of combination therapy o0.05 being considered significant. Statistical analyses were computed was estimated for patients who maintained treatment by the 24th with R (v 2.12.1. 2010-12-16, R Development Core Team 2010. Vienna, week (N ¼ 44). Both severe and intermediate groups showed Austria). improvement in EF domain scores. The severe group showed International Journal of Impotence Research (2013), 29 – 33 & 2013 Macmillan Publishers Limited Tadalafil and testosterone combination therapy JW Kim et al 31 Table 1. Comparison of initial patient characteristics and serum testosterone levels measured during study Total Severe Intermediate P Age (years) 56.26±7.57 56.90±8.51 55.80±6.90 0.62 Height (cm) 167.47±6.01 167.69±7.26 167.20±4.21 0.85 Weight (kg) 68.14±8.33 66.04±8.61 69.80±7.88 0.13 Waist (inch) 33.58±1.67 33.50±1.80 33.70±1.60 0.75 Testosterone (ng dl À 1) V1 (0 weeks) 260±54 208±30 299±28 o0.01 V3 (24 weeks) 656±171 602±169 698±165 0.06 V4 (36 weeks) 241±104 213±78 263±117 0.09 Diabetes
Load more

Recommended publications
  • Comparison of the Effects of High Dose Testosterone and 19-Nortestosterone to a Replacement Dose of Testosterone on Strength and Body Composition in Normal Men
    J. Steroid Biochem. Molec. Biol. Vol. 40, No. 4-6, pp. 607~12, 1991 0960-0760/91 $3.00 + 0.00 Printed in Great Britain Pergamon Press plc COMPARISON OF THE EFFECTS OF HIGH DOSE TESTOSTERONE AND 19-NORTESTOSTERONE TO A REPLACEMENT DOSE OF TESTOSTERONE ON STRENGTH AND BODY COMPOSITION IN NORMAL MEN KARL E. FRIEDL,* JOSEPH R. DETTORI, CHARLES J. HANNAN JR, TROY H. PATIENCE and STEPHENR. PLYMATE Exercise Physiology Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA and Department of Clinical Investigation, Madigan Army Medical Center, Tacoma, WA, U.S.A. Summary--We examined the extent to which supraphysiological doses of androgen can modify body composition and strength in normally virilized men. In doubly blind tests, 30 healthy young men received testosterone enanthate (TE) or 19-nortestosterone decanoate (ND), at 100mg/wk or 300mg/wk for 6 weeks. The TE-100mg/wk group served as replacement dose comparison, maintaining pretreatment serum testosterone levels, while keeping all subjects blinded to treatment, particularly through reduction in testicular volumes. Isokinetic strength measurements were made for the biceps brachii and quadriceps femoris muscle groups before treatment and 2-3 days after the 6th injection. Small improvements were noted in all groups but the changes were highly variable; a trend to greater and more consistent strength gain occurred in the TE-300mg/wk group. There was no change in weight for TE-100 mg/wk but an average gain of 3 kg in each of the other groups. No changes in 4 skinfold thicknesses or in estimated percent body fat were observed.
    [Show full text]
  • Testosterone, Injectable
    Clinical Criteria Subject: Testosterone, Injectable Document #: ING-CC-0026 Publish Date: 06/10/201909/23/2019 Status: ReviewedRevised Last Review Date: 03/18/201908/16/2019 Table of Contents Overview Coding References Clinical criteria Document history Overview This document addresses indications for the intramuscular (IM) and subcutaneous (SC) administration of testosterone injectables for the treatment of hormone deficient conditions. The following testosterone injection agents are included: • Testosterone cypionate intramuscular: Depo-Testosterone, generic testosterone cypionate • Testosterone enanthate: o Intramuscular: generic testosterone enanthate o Subcutaneous: Xyosted (auto-injector) • Testosterone undecanoate intramuscular: Aveed Testosterone is an androgen hormone responsible for normal growth and development of male sex characteristics. In certain medical conditions such as hypogonadism, the endogenous level of testosterone falls below normal levels. Primary hypogonadism includes conditions such as testicular failure due to cryptorchidism, bilateral torsion, orchitis, or vanishing testis syndrome; bilateral orchidectomy; and inborn errors in the biosynthesis of testosterone. Secondary hypogonadism, also called hypogonadotropic hypogonadism includes conditions such as gonadotropin-releasing hormone (GnRH) deficiency or pituitary-hypothalamic injury resulting from tumors, trauma, surgery, or radiation. In 2015, the Endocrine Society added the following amended recommendations: • Men with metabolic syndrome, who were previously unexamined by the 2010 Endocrine Society Clinical Practice Guidelines, may benefit from testosterone replacement therapy (TRT) based on improvements in biometrics and insulin sensitivity. Effects of TRT on similar endpoints in men with type 2 diabetes mellitus remain unclear; • Effects of TRT on erectile function, even in men refractory to phosphodiesterase type 5 inhibitors, and on quality of life in men with erectile dysfunction remain inconclusive (Seftel, 2015).
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • The Combined Cardiac Effect of the Anabolic Steroid, Nandrolone And
    ù1. v -¿. rlc) 77.- *n*hi.rnool oowol,ù*o ffi"/fu -lo *rn*(o fii'o fio¿o¿¿, /v&"ùún lonno **al cooaiæe';¿vfl"- oã. Benjamin D. Phillis, B.Sc. (Hons) Phatmacology Depattment of Clinical & Experimental Pharmacology Ftome Rd. , Medical School Noth Adelaide Univetsity ADEIAIDE SA 5OOO û.)r.'-*hr/7enveltîù Foremost, I would like to thank my two supervisors for the direction that they have given this ptojecr. To Rod, for his unfailing troubleshooting abiJity and to Jenny fot her advice and ability to add scientific rigour' Many thanks to Michael Adams for his technical assistance and especially fot performing the surgery for the ischaemia-reperfusion projects and for his willingness to work late nights and public holidays. Lastly I would like to thank my v¡ife for her extreme patience during the tumult of the last 5 years. Her love, suppoït, patience and undetstanding have been invaluable in this endeavout. Beniamin D. Phillis Octobet,2005 ADE,I-AIDE ii T*(¿t of Ao,t",tù DECI.ARATION I ACKNOWLEDGEMENTS il TABLE OF CONTENTS UI ABBREVIATIONS x ABSTRACT )ilr CÉIAPTER t-l Inttoduction 1-1 1.1 Background 1,-1, 1.2What ate anabolic stetoids? 7-1 1,3 General pharmacology of Anabolic steroids t-2 '1,-2 1.3.1 Genomic effects of anabolic steroids 1.3.2 Non-genomic effects of anabolic steroids 1-3 1.4 Clinical use of AS 1.-4 1.5 Patterns of AS abuse 1.-4 1.5.1 Steroid abuse by athletes 1.-+ 1.5.2 Stetoid abuse by sedentary teenagers r-6 1.5.3 Prevalence of abuse 1-6 1.5.4 Abuse ptevalence in Australia 1.-9 1.6 Cardiotoxicity of anabolic steroids r-9 1.6.1 Reduced cotonary flow 1.-1.1, 1,.6.2 Dtect myocatdial eff ects 1-1 5 1.6.3 Hypertension 1-21 1.7 Difficulties associated with anabolic steroid research 1.-24 1-25 1.8 The polydrug abuse Phenomenon 1.9 The pharmacology of cocaine 1-26 1.10 Pteparations 1-28 1-29 1.11 Metabolism lll 1-30 1.
    [Show full text]
  • Testosterone Enanthate Other Names: DELATESTRYL®
    For the Patient: Testosterone Enanthate Other names: DELATESTRYL® • Testosterone enanthate (tes-TOS-te-rone en-AN-thate) is a male hormone that is used to treat breast cancer in women. It is a clear liquid that is injected into a muscle. • A blood test may be taken from time to time. The dose and timing of your testosterone enanthate may be changed based on the test results and/or other side effects. • Tell your doctor if you have thyroid problems as testosterone enanthate may interact with thyroid tests (thyroid function is not affected). Tell your doctor if you have high cholesterol as testosterone enanthate may increase or decrease cholesterol. • Store testosterone enanthate at room temperature and out of the reach of children. • Use testosterone enanthate exactly as directed by your doctor. Make sure you understand the directions and feel comfortable with the injections. • Use a different site for each injection. Check with your nurse or doctor to find out which sites on your body can be used for injections. • Use each syringe once only to avoid infection. Place used syringes in a rigid plastic container with a lid. Discard the container as instructed by your treatment centre. Keep out of reach of children. • Other drugs such as warfarin (COUMADIN®) may interact with testosterone enanthate. Tell your doctor if you are taking this/these or any other drugs as you may need extra blood tests or your dose may need to be changed. Check with your doctor or pharmacist before you start taking any new drugs. • The drinking of alcohol (in small amounts) does not appear to affect the safety or usefulness of testosterone enanthate.
    [Show full text]
  • Testosterone C2270-A
    Drug and Biologic Coverage Criteria Effective Date: 04/12/2018 Last P&T Approval/Version: 07/28/2021 Next Review Due By: 08/2022 Policy Number: C2270-A Testosterone PRODUCTS AFFECTED ANDROID (methyltestosterone), ANDRODERM (testosterone topical), ANDROGEL (testosterone topical), AVEED (testosterone undecanoate), AXIRON (testosterone topical), DELATESTRYL (testosterone enanthate), DEPO-TESTOSTERONE (testosterone cypionate) FORTEST (testosterone topical), JATENZO (testosterone undeconoate), METHITEST (methyltestosterone), NATESTO (testosterone nasal gel),TESTIM* (testosterone topical), TESTOPEL (testosterone implant), TESTRED* (methyltestosterone), VOGELXO* (testosterone topical), XYOSTED (testosterone enanthate) COVERAGE POLICY Coverage for services, procedures, medical devices, and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines Documentation Requirements: Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement;
    [Show full text]
  • Hepatotoxic and Cardiotoxic Effects of Testosterone Enanthate Abuse on Adult Male Albino Rats
    Al-Azhar Med. J.( Medicine). Vol. 50(2), April, 2021, 1335 - 1348 DOI: 10.12816/amj.2021.158480 https://amj.journals.ekb.eg/article_158480.html HEPATOTOXIC AND CARDIOTOXIC EFFECTS OF TESTOSTERONE ENANTHATE ABUSE ON ADULT MALE ALBINO RATS By Mohamed Abd El-Aziz El-Gendy, Fouad Helmy El-Dabbah, Ashraf Ibrahim Hassan and Naser Abd El-Naby Awad* Departments of Forensic Medicine & Clinical Toxicology and Pathology*, Al-Azhar Faculty of Medicine, Egypt E-mail: [email protected] ABSTRACT Background: Anabolic androgenic steroids (AASs) represent a group of synthetic derivatives of testosterone created to maximize anabolic effects and minimize the androgenic ones. Athletes use anabolic androgenic steroids (AAS) to enhance performance regardless of the health risk they may impact in some persons. Objective: To study the histopathological and biochemical changes that could occur on liver and cardiac muscle after administration of doping dose (supraphysiological dose) of testosterone enanthate (one of AAS). Materials and Methods: One hundred (100) male albino rats were included in the present study and divided into six groups. Group (1a); negative control group, Group (1b) positive control group treated with therapeutic dose of testosterone Enanthate (10 mg /Kg body weight intramuscular / I.M weekly for 12 weeks), group (2) was treated with doping dose of testosterone enanthate (60 mg /Kg body weight/ I.M for 4 weeks), group (3) was treated with treated with doping dose of testosterone enanthate (60 mg /Kg body weight / I.M weekly for 8 weeks), group (4) treated with doping dose of testosterone enanthate (60 mg /Kg body weight / I.M weekly for 12 weeks), group (5a) treated with doping dose of testosterone enanthate (60 mg /Kg body weight/ I.M/ weekly for 12 weeks followed by 2 weeks of treatment discontinuation) , group (5b) treated with doping dose of testosterone enanthate (60 mg /Kg body weight/ I.M weekly for 12 weeks followed by 4 weeks of treatment discontinuation).
    [Show full text]
  • Effects of Nandrolone Stimulation on Testosterone Biosynthesis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio istituzionale della ricerca - Università di Palermo ORIGINAL RESEARCH ARTICLE 1385 JournalJournal ofof Cellular Effects of Nandrolone Physiology Stimulation on Testosterone Biosynthesis in Leydig Cells CRISTOFORO POMARA,1,2* ROSARIO BARONE,3,4 ANTONELLA MARINO GAMMAZZA,3,4 CLAUDIA SANGIORGI,4 FULVIO BARONE,1,5 ALESSANDRO PITRUZZELLA,3,6 NICOLA LOCOROTONDO,7 FRANCESCA DI GAUDIO,8 MONICA SALERNO,1 FRANCESCA MAGLIETTA,9 ANTONIO LUCIANO SARNI,1 VALENTINA DI FELICE,4 3,4 1 FRANCESCO CAPPELLO, AND EMANUELA TURILLAZZI 1Department of Forensic Pathology, University of Foggia, Foggia, Italy 2Department of Anatomy, University of Malta, Msida, Malta 3Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy 4Department of Experimental Biomedicine and Clinical Neurosciences (BioNeC), University of Palermo, Palermo, Italy 5Department of Radiology, Scientific Institute Hospital “Casa Sollievo della Sofferenza”, San Giovanni Rotondo (FG), Italy 6Department of Neuroscience, Mental Health and Sense Organs (Nesmos), Sapienza University of Rome, Rome, Italy 7Locorotondo Labs srl, Palermo, Italy 8Department of Pathobiology and Medical Biotechnology, University of Palermo, Palermo, Italy 9Department of Forensic Pathology, Sapienza University of Rome, Rome, Italy Anabolic androgenic steroids (AAS) are among the drugs most used by athletes for improving physical performance, as well as for aesthetic purposes. A number of papers have showed the side effects of AAS in different organs and tissues. For example, AAS are known to suppress gonadotropin-releasing hormone, luteinizing hormone, and follicle-stimulating hormone. This study investigates the effects of nandrolone on testosterone biosynthesis in Leydig cells using various methods, including mass spectrometry, western blotting, confocal microscopy and quantitative real-time PCR.
    [Show full text]
  • Determination of Testosterone Esters in Serum by Liquid Chromatography – Tandem Mass Spectrometry (LC-MS-MS)
    Department of Physics, Chemistry and Biology Final Thesis Determination of testosterone esters in serum by liquid chromatography – tandem mass spectrometry (LC-MS-MS) Erica Törnvall Final Thesis performed at National Board of Forensic Medicine 2010-06-03 LITH-IFM-EX--10/2263--SE Department of Physics, Chemistry and Biology Linköping University 581 83 Linköping, Sweden 1 Department of Physics, Chemistry and Biology Determination of testosterone esters in serum by liquid chromatography – tandem mass spectrometry (LC-MS-MS) Erica Törnvall Final Thesis performed at National Board of Forensic Medicine 2010-06-03 Supervisors Yvonne Lood Martin Josefsson Examiner Roger Sävenhed 2 Avdelning, institution Datum Division, Department Date 2010-06-03 Chemistry Department of Physics, Chemistry and Biology Linköping University Språk Rapporttyp ISBN Language Report category Svenska/Swedish Licentiatavhandling ISRN: LITH-IFM-EX--10/2263--SE Engelska/English Examensarbete _________________________________________________________________ C-uppsats D-uppsats Serietitel och serienummer ISSN ________________ Övrig rapport Title of series, numbering ______________________________ _____________ URL för elektronisk version Titel Title Determination of testosterone esters in serum by liquid chromatography – tandem mass spectrometry (LC-MS-MS) Författare Author Erica Törnvall Sammanfattning Abstract Anabolic androgenic steroids are testosterone and its derivates. Testosterone is the most important naturally existing sex hormone for men and is used for its anabolic effects providing increased muscle mass. Testosterone is taken orally or by intramuscular injection in its ester form and are available illegally in different forms of esters. Anabolic androgenic steroids are today analyzed only in urine. To differentiate between the human natural testosterone and exogenous supply the quote natural testosterone and epitestosterone is used.
    [Show full text]
  • Hepatotoxicity Associated with Illicit Use of Anabolic Androgenic Steroids in Doping
    Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2017; 21 (1 Suppl): 7-16 Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping R. SOLIMINI, M.C. ROTOLO, L. MASTROBATTISTA, C. MORTALI, A. MINUTILLO, S. PICHINI, R. PACIFICI, I. PALMI Department of Therapeutic Research and Medicines Evaluation, Drug Abuse and Doping Unit, Istituto Superiore di Sanità, Rome, Italy Abstract. – Anabolic Androgenic Steroids Since then , several synthetic analogs of testos - (AAS) abuse and misuse is nowadays a harmful terone, known as Anabolic Androgenic Steroids habit involving both professional or recreational (AAS) or designer steroids (e.g . methyltestos - athletes, as well as general population. AAS are also frequently present in over-the-counter di - terone in 1935 , nandrolone in 1950 and 1953, etary supplements without being declared in the testosterone esters from mid-1950s, stanozolol list of ingredients, leaving consumers unaware and oxymetholone in 1959 , oxandrolone in 1962) of the risks of adverse effects. Indeed, health have been produced in the attempt to minimize risks of AAS consumption in pharmaceutical the androgenic effects and improve the anabolic preparations or dietary complements seem still ones 1,2,7-9 . However , a successful complete sepa - underestimated and under-reported. The variety of complications due to AAS misuse involves ration of the anabolic and the androgenic proper - cardiovascular, central nervous, musculoskeletal ties has never been realized in the synthetic de - and genitourinary systems of both males and fe - rivatives of testosterone 1,2,10,11 . Among those, nan - males; psychiatric and behavioral effects, dam - drolone was the first compound which showed a ages to metabolic system, skin and mainly liver.
    [Show full text]
  • Intramuscular Testosterone
    Intramuscular Testosterone 1 Intramuscular (IM) testosterone products marketed in Canada* DIN Manufacturer Product Active Ingredient Strength Testosterone 00029246 Valeant Delatestryl 200 mg/ml Enanthate Testosterone 00030783 Pfizer Depo-Testosterone 100mg/ml Cypionate * Other products have been approved but are not currently being marketed.1 Confirm that ongoing use of testosterone is indicated Approved indication for IM testosterone therapy2: androgen replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Off-label uses3: hormone therapy for transgender males, sexual disorder, weight gain, others. 1 Potential alternatives for IM testosterone* DIN Product Strength Dosage Form Manufacturer 02322498 PMS-Testosterone 40mg oral capsule PMS 02421186 Taro-Testosterone 40 mg oral capsule TAR 02239653 2.5 mg/24 h transdermal Androderm ALL 02239653 5 mg/24 h patch 02249499 1% (12.5 mg/actuation) 02245345 Androgel 1% (25 mg/pack) transdermal gel BGP 02245346 1% (50 mg/pack) 02463792 Taro-Testosterone 1% (25 mg/pack) transdermal gel TAR 02463806 Gel 1% (50 mg/pack) 02280248 Testim 1% (50 mg/tube) transdermal gel PAL 02450550 Natesto 4.5% (5.5 mg/actuation) nasal gel ACP * All doses expressed as amount of testosterone delivered Considerations when choosing an alternate form of testosterone: GENERAL dosage recommendations for androgen deficiency o Testosterone enanthate or cypionate4,5: various doses and frequencies may be used. general: 75 -100 mg IM/subcutaneous (SC) every week . doses may range from 50 to 200 mg . frequencies may range from every 1 week to every 3-4 weeks (though the longer the interval, the greater the fluctuation in concentrations5 ) o Testosterone transdermal gel 1% 50 mg – 100 mg4,6 applied daily to an area of skin that will be covered.
    [Show full text]
  • The Effects of Anabolic-Androgenic Steroids on Aging in Bodybuilders
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1-1-2003 The effects of anabolic-androgenic steroids on aging in bodybuilders Barbara Szlendakova Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Recommended Citation Szlendakova, Barbara, "The effects of anabolic-androgenic steroids on aging in bodybuilders" (2003). Retrospective Theses and Dissertations. 20055. https://lib.dr.iastate.edu/rtd/20055 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. The effects of anabolic-androgenic steroids on aging in bodybuilders by Barbara Szlendakova A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Genetics Program of Study Committee: Eric Henderson (Maj or Professor) Fredric Janzen Douglas King Iowa State University Ames, Iowa 2003 11 Graduate College Iowa State University This is to certify that the master's thesis of Barbara Szlendakova has met the requirements of Iowa State University Signatures have been redacted for privacy iii TABLE OF CONTENTS ABSTRACT v1 CHAPTER 1. INTRODUCTION 1 Cellular Aging and Telomeres 1 What are anabolic-androgenic steroids 2 Structure of anabolic-androgenic steroids 4 How do steroids work? 5 Modes of anabolic-androgenic steroid use 8 Oral preparations 8 Effectiveness of oral steroids 8 lnjectible preparations 12 Oil-based preparations 12 Water-based preparations 13 Transdermal preparations 15 Anabolic-androgenic steroid use 15 Medical uses of anabolic-androgenic steroids 16 Side effects of steroid abuse 17 CHAPTER 2.
    [Show full text]